Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.628
-0.032 (-1.94%)
Nov 21, 2024, 11:33 AM EST - Market open
Gain Therapeutics Revenue
In the year 2023, Gain Therapeutics had annual revenue of $55.18K, down -58.40%.
Revenue (ttm)
$55.18K
Revenue Growth
-58.40%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
41.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SCYNEXIS | 8.57M |
LAVA Therapeutics | 7.40M |
Serina Therapeutics | 3.16M |
OncoCyte | 709.00K |
Daxor | 154.21K |
Actinium Pharmaceuticals | 81.00K |
GANX News
- 6 weeks ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - GlobeNewsWire
- 2 months ago - Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire